<DOC>
	<DOCNO>NCT01075464</DOCNO>
	<brief_summary>This Phase Ib , open-label , dose-escalation study MEGF0444A combination bevacizumab , combination bevacizumab paclitaxel therapy locally advance metastatic solid tumor .</brief_summary>
	<brief_title>A Study Safety Pharmacology MEGF0444A Combination With Bevacizumab With Without Paclitaxel Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically document , incurable , metastatic solid malignancy progress failed respond regimen therapy know provide clinical benefit Specific Arm A : For patient undergoing optional mandatory exploratory MRI , least one tumor lesion represent liver , fixed peritoneal , neck , extremity , pelvic lesion measure &gt; /= 3 10 cm ( liver lesion ) &gt; = 2 10 cm ( lesion location ) use MRI Specific Arm B : Maximum two prior chemotherapy regimens metastatic disease Anticancer therapy within 3 week prior initiation study treatment Patients discontinue prior bevacizumab therapy due intolerable toxicity Leptomeningeal disease Active infection autoimmune disease Known clinically significant liver disease , include active viral , alcoholic , hepatitis , cirrhosis Known primary central nervous system ( CNS ) malignancy untreated active CNS metastasis Inadequately control hypertension ; history hypertensive crisis encephalopathy ; congestive heart failure ( New York Heart Association Class II great ) ; history myocardial infarction unstable angina within 6 month prior initiation study treatment History hemoptysis ; evidence bleed diathesis significant coagulopathy History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior initiation study treatment Serious , nonhealing wound , active gastrointestinal ulcer , untreated bone fracture Specific Arm B : Known significant hypersensitivity paclitaxel drug use vehicle cremophor Previous intolerance paclitaxel Grade &gt; = 2 sensory neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid Tumor</keyword>
</DOC>